DermaLabs blends dermatologist-led science with community-powered research. Using decentralized trials, AI imaging, and SKIN token incentives, we turn everyday skincare into measurable evidence. Together, we build transparent, inclusive, and accountable pathways for discovering and validating what truly works for your skin.

GoCART Therapeutics is building a new generation of safer, smarter cell therapies for cancer. Our technology uses a biological 'AND-gate'—a two-key safety system that only activates its 'kill' signal when it detects two distinct targets on a cancer cell. This logic-gated approach dramatically reduces the toxicity risks of current CAR-T therapies.

We are developing a new gene therapy to help our canine companions stay stronger, move more comfortably, and enjoy healthier lives as they age. By supporting muscle growth, easing pain, and calming inflammation linked to arthritis, our follistatin therapy aims to improve everyday mobility and overall wellbeing.

As we age, our bodies accumulate senescent, or “zombie", cells which are highly damaged, yet refuse to die. They disrupt tissue homeostasis, are toxic to neighboring cells and are associated with numerous age-related diseases. This project will utilize CRISPR gene-editing technology to find genes that are essential for keeping senescent cells alive, thus providing new drug targets to selectively eliminate them.

We’re building a safe, affordable, and ethically sourced ibogaine therapy for PTSD—using synthetic production, personalized protocols, and transparent governance to make effective treatment accessible worldwide.

Nootropics DAO is building the world's most effective global infrastructure for decentralized research, discovery, and commercialization of powerful solutions for human cognitive enhancement. By creating an open-science ecosystem that aligns professional researchers, citizen-scientists, and biohackers to govern a community-directed research and development pipeline with hyper-efficient feedback loops, Nootropics DAO is operating to become the dominant force in the rapidly growing nootropics industry.

The first human trial that will tell you - with blood - which training actually grows your brain. 100 Berlin gym-goers. 2 training arms. 200+ BDNF blood draws. All data on-chain in real time. All revenue and dataset usage feed the Bio Protocol’s buyback & research-funding loop. 4300+ workouts already tracked. Now we ignite the next stage to reach longevity orbit.

This project will design a new RNA therapeutic that nudges the longevity-linked FOXO3 gene into its health-promoting form to halt the tissue breakdown behind degenerative disc disease—opening a precise, scalable route to drugs that extend healthspan.

Relieva is redefining therapeutic innovation through the world’s first proprietary cannabis and hemp pre-roll blend engineered for targeted pain relief. Leveraging advanced cannabinoid and terpene research, Relieva integrates scientific precision, sustainable production, and blockchain-enabled IP tokenization to establish a new benchmark in functional medicine innovation and therapeutic transparency.

The galectin-3 Inhibitors project tests a small molecule under development for peripheral indications for treating neuroinflammation in an Alzheimer’s mouse model. By blocking galectin-3, it aims to reduce brain inflammation, with potential in other neurodegenerative diseases. Galectin-3 is involved in neuroinflammation, thereby the inhibitor has a potential to be used in multiple neurodegenerative diseases.

VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.

D1ckGPT is a BioAgent that makes your D1ck stronger by assessing its age and guiding you on how to reverse it. Trained on 600+ clinician-curated studies with its own Decentralized Knowledge Graph, every interaction enhances D1ckGPT's intelligence, revolutionizing traditional care and accelerating science and drug discovery in men's health. Whether it’s optimizing testosterone, boosting cognitive edge, or getting smarter about longevity.